Sökning: (L773:1619 7089) pers:(Sundin Anders 1954) >
Prospective observa...
Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs) : feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity
-
- Garske, Ulrike, 1963- (författare)
- Uppsala universitet,Radiologi,Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden
-
- Sandström, Mattias (författare)
- Uppsala universitet,Radiologi
-
- Fröss-Baron, Katarzyna (författare)
- Uppsala universitet,Endokrin tumörbiologi
-
visa fler...
-
- Lundin, Lars (författare)
- Uppsala universitet,Radiologi
-
- Hellman, Per (författare)
- Uppsala universitet,Endokrinkirurgi
-
- Welin, Staffan (författare)
- Uppsala universitet,Onkologisk endokrinologi
-
- Johansson, Silvia (författare)
- Uppsala universitet,Experimentell och klinisk onkologi
-
- Khan, Tanweera Shaheena (författare)
- Uppsala universitet,Endokrin tumörbiologi
-
- Lundqvist, Hans (författare)
- Uppsala universitet,Medicinsk strålningsvetenskap
-
- Eriksson, Barbro (författare)
- Uppsala universitet,Endokrin tumörbiologi
-
- Sundin, Anders, 1954- (författare)
- Uppsala universitet,Radiologi
-
- Granberg, Dan (författare)
- Karolinska Institutet,Uppsala universitet,Onkologisk endokrinologi
-
visa färre...
-
(creator_code:org_t)
- 2018-03-01
- 2018
- Engelska.
-
Ingår i: European Journal of Nuclear Medicine and Molecular Imaging. - : Springer Science and Business Media LLC. - 1619-7070 .- 1619-7089. ; 45:6, s. 970-988
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://link.springe...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- PURPOSE: Peptide receptor radionuclide therapy in patients with neuroendocrine tumours has yielded promising results. This prospective study investigated the feasibility of dosimetry of the kidneys and bone marrow during therapy and its impact on efficacy and outcome.METHODS: Lu-DOTA-octreotate with co-infusion of a mixed amino acid solution, and cycles were repeated until the absorbed dose to the kidneys reached 23 Gy or there were other reasons for stopping therapy. The Ki-67 index was ≤2% in 47 patients (23.5%), 3-20% in 121 (60.5%) and >20% in 16 (8%).RESULTS: In 123 patients (61.5%) the absorbed dose to the kidneys reached 23 Gy with three to nine cycles during first-line therapy; in no patient was a dose to the bone marrow of 2 Gy reached. The best responses (according to RECIST 1.1) were a complete response (CR) in 1 patient (0.5%), a partial response (PR) in 47 (23.5%), stable disease (SD) in 135 (67.5%) and progressive disease (PD) in 7 (3.5%). Median progression-free survival was 27 months (95% CI 22-30 months) in all patients, 33 months in those in whom the absorbed dose to the kidneys reached 23 Gy and 15 months in those in whom it did not. Median overall survival (OS) was 43 months (95% CI 39-53 months) in all patients, 54 months in those in whom the absorbed dose to the kidneys reached 23 Gy and 25 months in those in whom it did not. Median OS was 60 months in patients with a best response of PR or CR, 42 months in those with SD and 16 months in those with PD. Three patients (1.5%) developed acute leukaemia, 1 patient (0.5%) chronic leukaemia (unconfirmed) and 30 patients (15%) grade 3 or 4 bone marrow toxicity. Eight patients (4%) developed grade 2 kidney toxicity and one patient (0.5%) grade 4 kidney toxicity.CONCLUSIONS: Lu-DOTA-octreotate is feasible. Patients in whom the absorbed dose to the kidneys reached 23 Gy had a longer OS than those in whom it did not. Patients with CR/PR had a longer OS than those with SD. Bone marrow dosimetry did not predict toxicity.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Radiologi och bildbehandling (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Radiology, Nuclear Medicine and Medical Imaging (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- 177Lu-DOTA-octreotate
- Dosimetry
- Neuroendocrine tumour
- Outcome
- PRRT
- Toxicity
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Garske, Ulrike, ...
-
Sandström, Matti ...
-
Fröss-Baron, Kat ...
-
Lundin, Lars
-
Hellman, Per
-
Welin, Staffan
-
visa fler...
-
Johansson, Silvi ...
-
Khan, Tanweera S ...
-
Lundqvist, Hans
-
Eriksson, Barbro
-
Sundin, Anders, ...
-
Granberg, Dan
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Radiologi och bi ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
European Journal ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet